Although HDAC inhibitors and PLK1 inhibitors have been extensively studied, their proposed mechanism(s) of action have been tumor centric (Gutteridge et al., 2016; Eckschlager et al., 2017). This evidence concerns the gene HDAC9 and neoplasm.